L. Estrada, S. Marin, G. Cardona Peitx, A. Morales, E. Terricabras Mas, A. Bocos-Baelo, N. Feliu Mas, C. García-Castiñeira, S. Garcia-Xipell, C. Rodríguez-González, C. Quiñones
{"title":"4CPS-046 评估接受英夫利西单抗治疗的炎症性肠病患者的健康影响:纳入患者报告的结果测量指标(PROMs)","authors":"L. Estrada, S. Marin, G. Cardona Peitx, A. Morales, E. Terricabras Mas, A. Bocos-Baelo, N. Feliu Mas, C. García-Castiñeira, S. Garcia-Xipell, C. Rodríguez-González, C. Quiñones","doi":"10.1136/ejhpharm-2024-eahp.150","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":121840,"journal":{"name":"Section 4: Clinical pharmacy services","volume":"152 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"4CPS-046 Evaluation of health impact in infliximab-treated patients with inflammatory bowel disease: incorporation of patient reported outcome measures (PROMs)\",\"authors\":\"L. Estrada, S. Marin, G. Cardona Peitx, A. Morales, E. Terricabras Mas, A. Bocos-Baelo, N. Feliu Mas, C. García-Castiñeira, S. Garcia-Xipell, C. Rodríguez-González, C. Quiñones\",\"doi\":\"10.1136/ejhpharm-2024-eahp.150\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":121840,\"journal\":{\"name\":\"Section 4: Clinical pharmacy services\",\"volume\":\"152 3\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Section 4: Clinical pharmacy services\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/ejhpharm-2024-eahp.150\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Section 4: Clinical pharmacy services","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ejhpharm-2024-eahp.150","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
4CPS-046 Evaluation of health impact in infliximab-treated patients with inflammatory bowel disease: incorporation of patient reported outcome measures (PROMs)